ClinicalTrials.gg
CompletedNCT06126783Updated May 1, 2026

A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

A Phase 3 interventional study of IBI311 in Thyroid Eye Disease, TED, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
91
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.

Enrollment
19th of 45
91 · median 64
Started
2023
with 5 others
Phase 3
13 of 55
4 open now
Registered
21st of 55
by date
Lead sponsor
6 of 55
Innovent Biologics (Suzhou) Co. Ltd.

Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 19th largest by enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2023, is one of 13 in phase 3, and was the 21st registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Graves Ophthalmopathy with a site in China, or all of them as a file.
02

Study summary

A multicenter, open-label extension study evaluating the efficacy and safety of IBI311 in subjects with thyroid eye disease

Read the detailed description

This is a multicenter, open-label outreach study. Participants who have previously participated in and completed CIBI311A201 double-blind treatment can enter this study after signing informed consent. The study included an observation period and an open treatment period. Observation period: From weeks D0 to 24, all subjects will return to the research center every 8 weeks for disease evaluation. If the investigator determines that treatment is required based on predefined criteria, they will enter the open treatment period to receive IBI311 treatment; Otherwise, subjects will continue to be visited every 8 weeks until week 24. Open Treatment period: Subjects entering the open treatment period will receive 8 infusions of IBI311 (initial dose of 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W.

03

Conditions studied

  • Thyroid Eye Disease, TED

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Comply with the test procedure and voluntarily sign the ;
  2. Male or female subjects aged between 18 and 80 years (inclusive) at the time of FU1 visit;
  3. For subjects who completed CIBI311A201 double-blind treatment period, the cohort date from the end of CIBI311A201 study was no more than 28 days;
  4. If the subject is female, it should be or after surgical sterilization or FU1 visit urine pregnancy test negative and agree to take measures within 120 days from FU1 visit to the last dose Women of childbearing age; Male subjects should agree to use contraception within 120 days from the FU1 visit to the last dose.

Exclusion criteria

Exclusion Criteria:

  1. Visual dysfunction due to optic neuropathy, defined as a decrease of ≥2 lines of best corrected vision within the last 180 days, a new visual field defect, or color difference secondary to optic nerve involvementOften;
  2. Patients with corneal ulcers that the investigator determined did not resolve after treatment;
  3. When the FU1 visit predecessor was scheduled to receive orbital radiation therapy or surgery for TED, including orbital decompression, strabismus correction, and eyelid correction, or during the study periodEtc.;
  4. Poor thyroid function control was defined as free T3 or T4 deviating from the normal reference range of the local research center laboratory by more than 50% during FU1 visit;
  5. The presence of any other prior disease, metabolic disorder, abnormal results of physical examination or clinical laboratory examination, which may reasonably be suspected to cause in the use of the test drug, or shadow Diseases or conditions that place subjects at high risk for treatment complications, including, but not limited to, confirmed or clinically suspected inflammatory bowel disease and coagulation Blood dysfunction, history of acute cardiovascular and cerebrovascular disease or treatment within 180 days prior to FU1 visit (including but not limited to: cerebrovascular accident, transient cerebral ischemia, acute myocardial infarction) Death, unstable angina pectoris, coronary artery bypass grafting, percutaneous coronary intervention (except diagnostic angiography), severe arrhythmia, etc.), treatment within the past 5 years or A history of untreated (squamous cell carcinoma of the skin, basal cell carcinoma, carcinoma in situ of the cervix, prostate in situ, or thyroid that has been successfully resected without evidence of ) Other than papillary carcinoma), serious systemic infection, non-TED caused eye protrusion, etc.;
  6. At the time of FU1 visit, either ear was present: a history of tinnitus or other hearing impairment; Or abnormal pure tone audiometry (defined as 0.5 1 24 4 kHz mean bone conduction threshold ≥25 dB or either Bone conduction threshold under frequency ≥40 dB);
  7. When FU1 visited, (AST) or alanine aminotransferase (ALT) were 3 times higher than ;
  8. When FU1 was visited, (GFR) was \< 30 ml/min/1.73 m2 (MDRD formula: GFR =186× serum creatinine (mg/dl)).-1.154× (age) -0.203× (0.742 [if female]), unit conversion of blood creatinine: 1 μmol/L=0.0113 mg/dL);
  9. The presence of poorly controlled diabetes at FU1 visit (defined as ≥9.0% at FU1 visit or a new diabetes medication within 60 days prior to screening]Dose change of diabetes drugs currently prescribed > 10%);
  10. At FU1 visit, poorly controlled hypertension was present, with systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; Or FU1 adjusted blood pressure medication (dose or.) within 30 days prior to visit Type of drug); Renal artery stenosis; Or evidence of unstable blood pressure (including postural hypotension);
  11. A 12-lead showing a heart rate \< 50 beats/min or > 100 beats/min at the FU1 visit indicates active heart disease, or an ECG abnormality at the time of the FU1 visit, as the investigator believes Interfering with the interpretation of ECG results during follow-up, especially excluding > 500 ms;
  12. Subjects received systemic or local use of , , or biologics (CD20 antibody, interleukin) from the end of CIBI311A201 study until FU1 visit of this study-6 receptor antibody, tetulizumab, etc.) to treat TED;
  13. Subjects treated TED with selenium or biotin (except multivitamins containing selenium or biotin) from the end of CIBI311A201 study to before FU1 visit of this study;
  14. Subjects had participated in other interventionary clinical trials (e.g., for drugs, during their 5 half-lives, with older participants) from the end of the CIBI311A201 study until the FU1 visit of this study Allowed; Vitamins and minerals), or attempting to participate in other clinical trials during the study period;
  15. Pregnant and lactating female subjects;
  16. People who are known to be allergic to the ingredients of the drug, or have a pre-existing allergy to other monoclonal antibodies;
  17. Participants considered unsuitable for this clinical trial due to other reasons.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
91 participants (actual)

Study arms

  • Experimental
    IBI311

    The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W

    Drug: IBI311

Interventions

  • DrugIBI311

    The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W

06

What researchers measure

Primary outcomes

  1. The response rate of exophthalmos was studied.

    To evaluate the effect of IBI311 on the exophthalmos response rate in the study eye (defined as the percentage of subjects with an exophthalmos reduction of ≥2 mm from baseline in the study eye without an increase of ≥2 mm in the contralaterial eye).

    Time frame: After receiving IBI311 treatment for 24 weeks

Secondary outcomes

  1. Overall responder rate (i.e., percentage of subjects with a ≥ 2-point decrease in Clinical Activity Score [CAS] and a ≥ 2 mm decrease from baseline in proptosis in the study eye, and without corresponding deterioration in the fellow eye in the study eye

    Total ocular response rate in the study eyes after 4 /8 IBI311 treatments.

    Time frame: After receiving IBI311 treatment for 24 weeks

  2. To evaluate the effects of IBI311 on ocular CAS score.

    Percentage of subjects with a CAS value of 0 or 1 after 4 /8 IBI311 treatments.

    Time frame: After receiving IBI311 treatment for 24 weeks

  3. To evaluate the effects of IBI311 on exophthalmos.

    Mean change in exophthalmia from baseline in study eyes after 4 /8 IBI311 treatments.Efficacy of investigational eye therapy after 4 /8 IBI311 treatments

    Time frame: After receiving IBI311 treatment for 24 weeks

  4. To evaluate the efficacy of IBI311 in improving contralateral eye.

    After 4 /8 treatments with IBI311,The response rate of exophthalmos in the improving contralateral eye.

    Time frame: After receiving IBI311 treatment for 24 weeks

  5. To evaluate the efficacy of IBI311 in improving diplopia.

    Diplopia response rate after four/eight IBI311 treatments (defined as the percentage of subjects with diplopia at baseline with grade 1 reduction).

    Time frame: After receiving IBI311 treatment for 24 weeks

  6. To evaluate the effects of IBI311 on Graves' ophthalmopathy-specificquality of life (GO-QOL) scores.

    Mean change in total GO-QOL questionnaire scores from baseline after 4/8 IBI311 treatments;

    Time frame: After receiving IBI311 treatment for 24 weeks

  7. The rate of TED recurrence after discontinuation of IBI311 treatment was assessed

    Proportion of subjects entering open treatment due to relapse.

    Time frame: After receiving IBI311 treatment for 24 weeks

  8. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Incidence, association with the study drug and severity of ocular and systemic adverse events (AE), treatment-emergent adverse events (TEAE), and serious adverse events (SAE)

    Time frame: After receiving IBI311 treatment for 24 weeks

07

Study locations

1 site
  • Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai Municipality 200000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Sep 2025, 23 months.

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Nov 13, 2023
StartActual
Oct 20, 2023
Primary completionActual
Sep 23, 2025
CompletionActual
Sep 23, 2025
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06126783
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Oct 20, 2023
Primary completion
Sep 23, 2025
Completion
Sep 23, 2025
Last update
May 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IBI311

Start the discussion